กำลังโหลด
NASDAQHealthcareBiotechnology
ข้อมูลล่าสุด
US$10.69
+US$0.19 · +1.81%
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
ราคาปิดก่อนหน้า
US$10.69
+US$0.19 · +1.81%
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
ช่วงราคารายวัน
ปัจจุบัน US$10.69
ช่วง 52 สัปดาห์
ปัจจุบัน US$10.69
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ถือ
มูลค่า
62
ต่ำกว่ามูลค่า
ความเชื่อมั่น
65
เชิงบวก
ความเสี่ยง
49
ความเสี่ยงค่อนข้างสูง
โมเมนตัม
70
กำลังแข็งแกร่งขึ้น
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
ช่วงราคารายวัน
ปัจจุบัน US$10.69
ช่วง 52 สัปดาห์
ปัจจุบัน US$10.69
ผลที่ประกาศแล้วพร้อมประมาณการร่วมที่มีอยู่
ผลที่ประกาศแล้วพร้อมประมาณการร่วมที่มีอยู่
กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
iShares Russell 2000 ETFIWM16.48M0.02%78.27B USD0.19%US$278.94+0.49%
First Trust Small Cap Growth AlphaDEX FundFYC6.65M0.49%1.33B USD0.70%US$115.36+1.35%
iShares Biotechnology ETFIBB5.93M0.06%10.28B USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO4.77M0.03%18B USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO4.56M0.03%13.97B USD0.24%US$356.78+0.94%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP2.73M0.10%2.61B USD0.20%US$66.35+1.13%
First Trust Small Cap Core AlphaDEX FundFYX2.45M0.18%1.34B USD0.58%US$135.38+0.28%
Janus Henderson Small Cap Growth Alpha ETFJSML2.44M0.68%360.88M USD0.30%US$87.477+1.00%iShares Russell 2000 ETFIWMFirst Trust Small Cap Growth AlphaDEX FundFYCiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Kensho New Economies Composite ETFKOMPFirst Trust Small Cap Core AlphaDEX FundFYXJanus Henderson Small Cap Growth Alpha ETFJSMLเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน
